|
|
|
| Meta-analysis on effect of compound ganglioside injection in treating cerebral infarction |
| GUO Lisha1, LIN Feixue2, WANG Xianbin1, CHANG Lujie3, ZHENG Jinghui4, DU Xuqiang1 |
1 Department of Emergency,Binzhou Medical University Hospital,Binzhou 256603,P.R.China;
2 Deparment of Cardiology,Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine;
3 Gastroenterology Departments, Binzhou Medical University Hospital;
4 Department of Science and Technology, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine |
|
|
|
|
Abstract Objective To systematically evalutate the clinical efficacy and safty of compound ganglioside injection(GM1)in treating cerebral infarction(CI) of adults.Methods Computer retrievals were made in CNKI,VIP,Wanfang Data, Medline, Embase and relevant literature references(before October 2015),and manual retrievals were made for journals and conference papers.We collected randomized controlled trials concerning compound GM1 in the treatment of CI.The quality of included references was evaluated according to literatures recommended by Cochrane Handbook.RevMan 5.3 software was applied in the statistical treatment. Finally, a total of 36 randomized controlled trials were included,covering 2 076 patients (including 1 041 patients in the compound GM1-treated group and 1 035 patients in the control group ).Results Meta-analysis results showed that the routine treatment combined with compound GM1 could improve the treatment efficiency of CI [RR =1.28, 95% CI(1.23~1.34)],improve the cure rate [RR=1.46, 95%CI(1.28~1.67)] and reduce the neurological deficit scores [MD =-9.08, 95% CI(-11.61~-6.54)] with statistical differences.Of the included studies 5 cases of skin rash appeared,7 cases of alanine Aminotransferase (GPT) increased.After stopping drugs,these above disappeared without damage to liver and kidney function.Conclusion So far,limited evidences in this study proved that the application of compound GM1 in the treatment of CI can enhance the clinical efficiency. However,because of the low quality of the included trials,more well-designed and large scale multi-center randomized controlled trials shall be made in the future.
|
|
Received: 22 March 2016
|
|
|
|
|
|
[1] 费娜,蒋广军.神经节苷脂GM1治疗急性脑梗死疗效观察[J].济宁医学院学报,2004,27(3):48-49.
[2] 夏涛,刘晓玲.神经节苷脂治疗急性脑梗死的疗效观察[J].海峡药学,2005,17(3):136-137.
[3] 闫斌,牛好敏,刘远红,等. 神经节苷脂GM1治疗急性脑梗死的临床观察[J].临床荟萃,2006,21(22):1646-1647.
[4] 钟伟,王良,王爱岳.神经节苷脂治疗急性脑梗死的疗效观察[J].中国实用神经疾病杂志,2006,9(3):80-81.
[5] 冶学兰.神经节苷脂治疗急性脑梗死70例疗效观察[J].山东医药,2008,48(25):91-92.
[6] 朱晔宁.神经节苷脂治疗急性脑梗死的疗效观察[J].临床和实验医学杂志,2008,7(11):23-24.
[7] 关明,张玉杰,李广印,等.单唾液酸四己神经节苷脂治疗急性脑梗死临床疗效初探[J].中国临床实用医学,2009,3(1):61-62.
[8] 赵航.神经节苷脂治疗急性脑梗死的疗效观察[J].中国误诊学杂志,2009,9(10):2349.
[9] 韩卫东.神经节苷脂对脑梗死患者神经功能缺损的影响[J].山东医药,2011,51(41):67-68.
[10] 谢艳,董卫华.神经节苷脂治疗急性脑梗死临床效果观察[J].内蒙古中医药,2011,22(30):96-97.
[11] 王文全. 神经节苷脂治疗急性脑梗死的临床疗效观察[J].内蒙古医学杂志,2012,44(2):181-183.
[12] 肖悠美.单唾液酸四己糖神经节苷脂治疗急性脑梗死疗效观察[J].中国实用神经疾病杂志,2012,15(3):44-45.
[13] 杨元文.单唾液酸四已糖神经节苷脂钠注射液治疗急性脑梗死的有效性及不良反应分析[J].养生保健指南(中旬刊),2012(2):21-23.
[14] 张倩,姚蔚,史楠,等. 神经节苷脂治疗急性期脑梗死的临床疗效观察[J].中国保健营养(中旬刊),2012(5):99-100.
[15] 艾尔肯.神经节苷脂GM1治疗急性脑梗死66例临床疗效分析[J].中国急救医学,2013,33(1):68-69.
[16] 葛照琴.神经节苷脂对脑梗死患者肢体运动功能的改善效果观察[J].医学信息,2013(29):149-151.
[17] 孟祥丽,刘志荣.小剂量单唾液酸四己酸神经节苷脂治疗急性脑梗死疗效观察[J].内蒙古医学杂志,2013,45(1):94-95.
[18] 孙丹峰,王发明,庞伟茂.神经节苷脂对急性脑梗死中患者神经、运动功能的影响[J].中国药师,2013;16(1):101-102.
[19] 李晓鹤,罗毅.单唾液酸四己糖神经节苷脂在急性脑梗死的应用价值[J].中国实用神经疾病杂志,2014,17(11):79-80.
[20] 李一心.神经节苷脂治疗老年急性脑梗死的临床疗效及其对炎症因子的影响[J].中外医学研究,2014,12(9):31-32.
[21] 王丽燕.单唾液酸神经节苷脂治疗脑梗死78例疗效观察[J],中国实用医药. 2014,9(34):113-114.
[22] 张萍,冉东秀.单唾液酸四己糖神经节苷脂改善脑梗死患者神经功能缺损症状的疗效观察[J].中国医学创新.2014,05.53-54.
[23] 齐夏.神经节苷脂治疗老年急性脑梗死的临床疗效及作用机制研究[J].世界最新医学信息文摘,2015,15(12):16-17.
[24] Vickers A,Goyal N, Harland R,et al.Do certain countries produce only positive results? A systematic review of controlled trials[J].Control Clini Trials,1998;19(2):159-66.
[25] Mueller K F,Meerpohl J J, Briel M,et al. Detecting,quantifying and adjusting for publication bias in meta-analyses:protocol of a systematic review on methods[J].Syst Rev,2013,2:60.
[26] Moher D, Pham B,Jones A,et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?[J] Lancet,1998,352(9128):609-613.
[27] 丁明甫,何成奇,卫茂玲.临床试验与临床试验中心. 中国临床康复,2003,7(3):355-358.
[28] 周登远.临床试验文献质量评价量表的制作及应用 [D].天津:天津医科大学,2005.
[29] Bian Z,Liu B,Moher D,et al.Consolidated standards of reporting trials (CONSORT) for traditional Chinese medicine: current situation and future development[J].Front Med,2011,5(2):171-177. |
| [1] |
WANG Shanshan, JIANG Xingyue, LIU Xinjiang, GUO Lantian, MAO Xijin, SU Qian. Ultra-early diagnosis of Hyun-speed dual-source CT perfusion imaging in acute ischemic cerebral infarction in dogs[J]. 滨州医学院学报, 2019, 42(5): 346-348. |
| [2] |
JIA Teng, GU Xiaojie, LIU Hongjian, XU Haitao, ZHANG Qingguang. Postoperative adjuvant chemotherapy for stage IB non-small-cell lung cancer:A systematic review and meta-analysis[J]. 滨州医学院学报, 2019, 42(4): 281-284. |
| [3] |
ZHOU Jun, JIN Lairun, TAO Mengjun, YUAN Hui. A meta-analysis of risk factors for neuropsychiatric lupus erythematosus[J]. 滨州医学院学报, 2019, 42(2): 84-87. |
| [4] |
. [J]. 滨州医学院学报, 2019, 42(1): 66-68. |
| [5] |
XU Jing, GE Ruli, HOU Yiwei. Effect of mNGF in the treatment and levels of serum MBP,NSE,and VEGF in patients with cerebral infarction[J]. 滨州医学院学报, 2018, 41(3): 171-173. |
| [6] |
GUI Qian, FENG Hongxuan, WU Guanhui, CHENG Qingzhang. Clinical significance in combined detection of serum Lipoprotein-associated phospholipase A2 and C-reactive protein in patients with acute cerebral infarction[J]. 滨州医学院学报, 2018, 41(3): 180-182. |
|
|
|
|
